ITGAM and Miyoshi myopathy: The number of living MM (3H2+CD11b−) and 3H2−CD11b− cells was significantly higher in both week 2 and week 3 5T33MM BM (Figure 2C and 2D), whereas the enhanced survival of CD11b+ cells was mostly observed in week 3 5T33MM BM (Figure 2D).